Altered interferon defense in children with dynamically changed infectious mononucleosis

Cover Page

Cite item

Abstract

The state of the interferon system in 38 children with acute infectious mononucleosis (IM) caused by the Epstein—Barr virus was analyzed. Interferon status was examined in accordance with F.I. Ershov method based on assessing related biological activity by measuring interferon level in the blood serum or produced by blood cells. The aim of the study was to gain scientifically justified data for use of interferon preparations or interferonogens in IM combination therapy. For this, interferon status in children with acute IM was compared with that one not only in control group (30 healthy children, aged 3—6 and 20 children, aged 7—14 years, examined earlier to create an intra-laboratory interferon normal range), but also in children with lacunar angina or acute respiratory viral infection, hospitalized in the same department of the clinic and comparable with the main group in severity of the condition. In addition, we assessed changes in IFN-status in IM patients receiving no interferon preparations, one month after the disease onset. The study showed that patients with moderate acute IM were featured with decreased potential of blood leukocytes to virus-induced IFNa and mitogen-induced IFNy production observed with almost similar or some lower rate as in the control group of children hospitalized with angina or acute respiratory viral infection. Peripheral blood cells from moderate acute IM patients in the 3-6-year age group were found to produce virtually unaltered interferon level, whereas almost sole IFN-alpha production was affected in 7-14-year-old patients. Moreover, in 7-14-year old patients the level 1 and level 2 of IFNa deficiency was observed in 38% and 6% of cases, respectively. It is likely it was just this patient group requiring administration of any IFNa replacement therapy. As few as 12 children were re-examined after discharge from the clinic. Initially, prevalence and severity level of impaired interferon production in this subgroup did not differ from that one for total patient sample, whereas 1 month later a host potential to produce both IFNa and IFNy even without therapy acting on interferon system was noted to be moderately augmented.

About the authors

E. A. Kukushkina

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: docelena.k@yandex.ru
ORCID iD: 0000-0002-0561-3565

Junior Researcher, Laboratory for the Study of Cellular and Molecular Bases of Immunity.

Moscow

Russian Federation

S. I. Koteleva

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: felileo@yandex.ru
ORCID iD: 0000-0003-1878-2234

PhD (Medicine), Leading Researcher, Laboratory for the Study of Cellular and Molecular Bases of Immunity.

Moscow

Russian Federation

M. S. Blyakher

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: msb2222@list.ru
ORCID iD: 0000-0003-3480-6873

PhD, MD (Medicine), Professor, Head of the Laboratory for the Study of Cellular and Molecular Bases of Immunity.

Moscow Russian Federation

I. M. Fedorova

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Author for correspondence.
Email: vestnik-07@mail.ru
ORCID iD: 0000-0002-0335-2752

Irina M. Fedorova - PhD (Medicine), Leading Researcher, Laboratory for the Study of Cellular and Molecular Bases of Immunity.

125212 Moscow, Admiral Makarov str., 10, Phone: +7 (903) 107-60-67. Fax: (495) 452-18-30

Russian Federation

Z. K. Ramazanova

G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: rzarema@mail.ru
ORCID iD: 0000-0002-9314-3312

PhD (Medicine), Senior Researcher, Laboratory for the Study of Cellular and Molecular Bases of Immunity.

Moscow

Russian Federation

N. N. Zvereva

Pirogov Russian National Research Medical University

Email: zvereva_nadezhda@mail.ru
ORCID iD: 0000-0003-2699-0439

PhD (Medicine), Associate Professor, Department of Infectious Diseases in Children.

Moscow

Russian Federation

E. V. Novosad

Pirogov Russian National Research Medical University

Email: novyi@yandex.ru
ORCID iD: 0000-0001-9336-0969

PhD (Medicine), Associate Professor, Department of Infectious Diseases in Children.

Moscow

Russian Federation

A. A. Samkov

Infectious Hospital No. 1 Moscow Department of Healthcare

Email: alex-ridiger@mail.ru

Infectious Disease Physician, Pediatrician, Head of the Department No. 13.

Moscow

Russian Federation

M. V. Bazarova

Infectious Hospital No. 1 Moscow Department of Healthcare

Email: 03bmv@mail.ru

Epidemiologist, Deputy Chief Physician.

Moscow

Russian Federation

References

  1. Боковой А.Г., Домрачева М.Е. Клиническое значение иммунологических показателей при инфекционном мононуклеозе у детей // Детские инфекции. 2006. № 3. С. 18—22.
  2. Кузнецов С.И., Смирнов Н.А., Латаш В.Г., Ариненко Р.Ю., Аникин В.Б., Носикова Е.В. Влияние интерферонотерапии на интерфероновый статус больных и функциональную активность некоторых клеточных популяций крови // Медицинская иммунология. 2003. Т. 5, № 1—2. С. 73—80.
  3. Куртасова Л.М., Шакина Н.А., Шмидт А.Р. Клеточная чувствительность к интерферону-а2 in vitro у детей с инфекционным мононуклеозом, вызвынным вирусом Эпштейна—Барр // Медицинская иммунология. 2016. Т. 18, № 1. C. 79—84.
  4. Образцова Е.В., Осидак Л.В., Головачева Е.Г. Препараты интерферона и его индукторов при гриппе и ОРИ у детей // Детские инфекции. 2010. № 1. С. 35—40.
  5. Определение интерферонового статуса как показателя неспецифической резистентности организма человека: практические рекомендации Ассоциации специалистов и организаций лабораторной службы «Федерация лабораторной медицины»; под ред. Ф.И. Ершова. М., 2018. 26 с.
  6. Попова О.А., Чуйкова К.И., Якимов В.Л., Минакова Ю.В., Петрова Е.И. Клинико-иммунологические показатели у детей с инфекционным мононуклеозом на фоне противовирусной терапии в острый период и в катамнезе // Лечащий врач. 2016. № 11. С. 92—95.
  7. Савенкова М.С., Караштина О.В., Шабат М.Б., Красева Г.Н., Абрамова Н.А., Красева Т.Е. Интерфероновый статус и выбор индукторов интерферонов у часто болеющих детей // Детские инфекции. 2016. № 2. С. 45 — 51. doi: 10.22627/2072-8107-2016-15-2-45-51
  8. Самсыгина Г.А., Трошина В.В., Перцева А.Д. Особенности механизмов врожденного и адаптивного иммунитета у часто болеющих детей // Вестник Российского государственного медицинского университета. 2013. № 2. С. 42—46.
  9. Тимченко В.Н., Баннова С.Л., Калинина Н.М., Булина О.В., Выжлова Е.Н., Назарова А.Н., Федорова А.В. Клиническая и иммунологическая эффективность рекомбинантного интерферона альфа^ при остром Эпштейна—Барр вирусном мононуклеозе у детей дошкольного возраста // Детские инфекции. 2016. № 3. С. 30—37.
  10. Хмилевская С.А., Зайцева И.А., Зрячкин Н.И., Бережнова И.А. Особенности состояния системы гемостаза и иммунопатологические реакции при Эпштейна—Барр вирусной инфекции у детей // Журнал инфектологии. 2015. T. 7, № 2. С. 75—82.
  11. Хохлова З.А., Попова О.А., Чуйкова К.И., Якимов В.Л., Минакова Ю.В., Петрова Е.И. Инфекционный мононуклеоз у детей: особенности течения заболевания в зависимости от видов противовирусной терапии // Журнал инфектологии. 2017. T. 9, № 3. С. 67—74. doi: 10.22625/2072-6732-2017-9-3-67-74
  12. Шведова Н.М., Михайлова Е.В., Цека Ю.С., Чудакова Т.К. Инфекционный мононуклеоз у детей: клинико-лабораторное обоснование и экономическая эффективность применения иммунокорректоров // Саратовский научно-медицинский журнал. 2013. Т. 9, № 3. С. 512-517.
  13. Azzi T., Lunemann A., Murer A., Ueda S., Beziat V., Malmberg K.J., Staubli G., Gysin C., Berger C., Munz C., Chijioke O., Nadal D. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood. 2014, vol. 124, no. 16, рр. 2533-2543. doi: 10.1182/blood-2014-01-553024
  14. Chijioke O., Azzi T., Nadal D., Munz C. Innate immune responses against Epstein—Barr virus infection. J. Leucoc. Biol., 2013, vol. 94, no. 6, pp. 1185-1190. doi: 10.1189/jlb.0313173
  15. Gujer C., Murer A., Muller A., Vanoaica D., Sutter K., Jacque E., Fournier N., Kalchschmidt J., Zbinden A., Capaul R., Dzvonek A., Mondon P., Dittmer U., Munz C. Plasmacytoid dendritic cells respond to Epstein—Barr virus infection with a distinct type I interferon subtype profile. Blood Adv., 2019, vol. 3, no. 7, pp. 1129-1144. doi: 10.1182/bloodadvances.2018025536
  16. Hislop A.D. Early virological and immunological events in Epstein—Barr virus infection. Curr. Opin. Virol., 2015, vol. 15, рр. 75-79. doi: 10.1016/j.coviro.2015.08.002
  17. Hoshino Y., Nishikawa K., Ito Y., Kuzushima K., Kimura H. Kinetics of Epstein—Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis. J. Clin.Virol., 2011, vol. 50, no. 3, pp. 244-246. doi: 10.1016/j.jcv.2010.11.017
  18. Kwaa A.K.R., Talana C.A.G., Blankson J.N. Interferon alpha enhances NK cell function and the suppressive capacity of HIV-specific CD8+ T cells. J. Virol., 2019, vol. 93, no. 3: e01541-18. doi: 10.1128/JVI.01541-18
  19. Micco L., Peppa D., Loggi E., Schurich A., Jefferson L., Cursaro C., Panno A.M., Bernardi M., Brander C., Bihl F., Andreone P., Maini M.K. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J. Hepatol., 2013, vol. 58, no. 2, pp. 225-233. doi: 10.1016/j.jhep.2012.09.029
  20. Rolinski J., Grywalska E., Pyzik A., Dzik M., Opoka-Winiarska V., Surdacka A., Maj M., Burdan F., Pirozynski M., Grabarczyk P., Staroslawska E. Interferon alpha as antiviral therapy in chronic active Epstein-Barr virus disease with interstitial pneumoniacase report. BMC Infect. Dis., 2018, vol. 18, no. 190. doi: 10.1186/s12879-018-3097-6
  21. Wilson W.H., Kingma D.W., Raffel M., Wittes R.E., Jaffe E.S. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood, 1996, vol. 87, no. 11, pp. 4531—4537.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Kukushkina E.A., Koteleva S.I., Blyakher M.S., Fedorova I.M., Ramazanova Z.K., Zvereva N.N., Novosad E.V., Samkov A.A., Bazarova M.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies